| Medical and Health Sciences | Lifetime | 324 | US 180 | 99.99 |
| Psychology and Behavioral Sciences | Lifetime | 48 | US 28 | 99.98 |
| Psychology and Behavioral Sciences | 2021-2025 | 14 | US 3 | 99.96 |
| Medical and Health Sciences | 2021-2025 | 318 | US 113 | 99.94 |
| Clinical Psychology | Lifetime | 37 | US 25 | 99.96 |
| Social Psychology | Lifetime | 31 | US 23 | 99.94 |
| Psychiatry and Mental health | Lifetime | 37 | US 20 | 99.90 |
| General Health Professions | Lifetime | 191 | US 100 | 99.76 |
| Public, Environmental and Occupational Health | Lifetime | 240 | US 113 | 99.67 |
| Clinical Pharmacology | Lifetime | 196 | US 86 | 99.20 |
| Cognitive Psychology | Lifetime | 459 | US 245 | 98.63 |
| Emergency Medicine | Lifetime | 219 | US 122 | 98.28 |
| Philosophy of Mind, Language and Cognitive Science | Lifetime | 248 | US 112 | 97.04 |
| Health | Lifetime | 462 | US 252 | 96.96 |
| Clinical Psychology | 2021-2025 | 11 | US 2 | 99.93 |
| Public, Environmental and Occupational Health | 2021-2025 | 45 | US 16 | 99.62 |
| Social Psychology | 2021-2025 | 32 | US 10 | 99.63 |
| General Health Professions | 2021-2025 | 68 | US 32 | 99.53 |
| Psychiatry and Mental health | 2021-2025 | 117 | US 41 | 97.84 |
| Clinical Pharmacology | 2021-2025 | 117 | US 36 | 96.05 |
| Emergency Medicine | 2021-2025 | 86 | US 36 | 95.73 |
| Econometrics and Quantitative Economics | 2021-2025 | 804 | US 221 | 94.86 |
| Epidemiology | 2021-2025 | 740 | US 262 | 92.77 |
| Cognitive Psychology | 2021-2025 | 374 | US 138 | 92.64 |
| Applied Psychology | 2021-2025 | 120 | US 40 | 88.76 |
| Mental Health Treatment and Access | Lifetime | 6 | US 3 | 99.95 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 13 | US 9 | 99.54 |
| Suicide and Self-Harm Studies | Lifetime | 10 | US 7 | 99.75 |
| Healthcare Decision-Making and Restraints | Lifetime | 7 | US 5 | 99.58 |
| Psychiatric care and mental health services | Lifetime | 8 | US 4 | 99.66 |
| Schizophrenia research and treatment | Lifetime | 23 | US 14 | 99.88 |
| Child and Adolescent Psychosocial and Emotional Development | Lifetime | 61 | US 44 | 99.85 |
| Pharmaceutical studies and practices | Lifetime | 25 | US 17 | 99.50 |
| Maternal Mental Health During Pregnancy and Postpartum | Lifetime | 38 | US 19 | 99.50 |
| Poisoning and overdose treatments | Lifetime | 18 | US 6 | 99.32 |
| Opioid Use Disorder Treatment | Lifetime | 30 | US 19 | 99.46 |
| Emergency and Acute Care Studies | Lifetime | 75 | US 41 | 99.26 |
| Attention Deficit Hyperactivity Disorder | Lifetime | 58 | US 37 | 99.38 |
| Primary Care and Health Outcomes | Lifetime | 96 | US 62 | 99.15 |
| Bipolar Disorder and Treatment | Lifetime | 74 | US 39 | 99.41 |
| Treatment of Major Depression | Lifetime | 70 | US 35 | 99.33 |
| Healthcare Policy and Management | Lifetime | 213 | US 158 | 98.70 |
| Substance Abuse Treatment and Outcomes | Lifetime | 132 | US 92 | 98.98 |
| Healthcare professionals’ stress and burnout | Lifetime | 132 | US 57 | 98.20 |
| Health disparities and outcomes | Lifetime | 351 | US 156 | 98.53 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 637 | US 299 | 98.51 |
| Prenatal Substance Exposure Effects | Lifetime | 104 | US 77 | 98.22 |
| COVID-19 and Mental Health | Lifetime | 355 | US 89 | 97.20 |
| Mental Health and Psychiatry | Lifetime | 171 | US 82 | 98.49 |
| Child and Adolescent Health | Lifetime | 287 | US 140 | 97.08 |
| Psychosomatic Disorders and Their Treatments | Lifetime | 329 | US 118 | 97.52 |
| Cannabis and Cannabinoid Research | Lifetime | 387 | US 170 | 96.99 |
| Electroconvulsive Therapy Studies | Lifetime | 147 | US 74 | 97.55 |
| Pain Management and Opioid Use | Lifetime | 263 | US 141 | 97.24 |
| Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes | Lifetime | 415 | US 207 | 97.70 |
| Homelessness and Social Issues | Lifetime | 601 | US 407 | 96.52 |
| Adolescent and Pediatric Healthcare | Lifetime | 512 | US 267 | 96.01 |
| Sleep and related disorders | Lifetime | 672 | US 311 | 96.00 |
| Cardiac Health and Mental Health | Lifetime | 868 | US 403 | 95.04 |
| Digital Mental Health Interventions | Lifetime | 549 | US 210 | 94.21 |
| Pharmaceutical industry and healthcare | Lifetime | 252 | US 152 | 92.31 |
| Obsessive-Compulsive Spectrum Disorders | Lifetime | 854 | US 363 | 93.59 |
| Youth Substance Use and School Attendance | Lifetime | 342 | US 194 | 87.05 |
| Homicide, Infanticide, and Child Abuse | Lifetime | 883 | US 446 | 83.24 |
| Gun Ownership and Violence Research | Lifetime | 595 | US 498 | 82.58 |
| Suicide and Self-Harm Studies | 2021-2025 | 1 | US 1 | 99.65 |
| Mental Health Treatment and Access | 2021-2025 | 7 | US 4 | 99.76 |
| Child and Adolescent Psychosocial and Emotional Development | 2021-2025 | 18 | US 8 | 99.47 |
| Opioid Use Disorder Treatment | 2021-2025 | 25 | US 19 | 98.87 |
| COVID-19 and Mental Health | 2021-2025 | 160 | US 24 | 98.10 |
| Substance Abuse Treatment and Outcomes | 2021-2025 | 41 | US 24 | 98.25 |
| Poisoning and overdose treatments | 2021-2025 | 12 | US 6 | 96.58 |
| Health disparities and outcomes | 2021-2025 | 146 | US 61 | 96.91 |
| Healthcare Policy and Management | 2021-2025 | 58 | US 49 | 97.01 |
| Maternal Mental Health During Pregnancy and Postpartum | 2021-2025 | 102 | US 38 | 96.73 |
| Schizophrenia research and treatment | 2021-2025 | 105 | US 20 | 97.42 |
| Pain Management and Opioid Use | 2021-2025 | 49 | US 34 | 96.18 |
| Emergency and Acute Care Studies | 2021-2025 | 152 | US 71 | 95.62 |
| Primary Care and Health Outcomes | 2021-2025 | 185 | US 106 | 93.09 |
| Prenatal Substance Exposure Effects | 2021-2025 | 135 | US 93 | 91.69 |
| Healthcare Decision-Making and Restraints | 2021-2025 | 87 | US 23 | 89.38 |
| Youth Substance Use and School Attendance | 2021-2025 | 32 | US 10 | 89.64 |
| Sleep and related disorders | 2021-2025 | 584 | US 185 | 90.92 |
| Homelessness and Social Issues | 2021-2025 | 458 | US 241 | 88.27 |
| Digital Mental Health Interventions | 2021-2025 | 531 | US 157 | 88.37 |
| Psychosomatic Disorders and Their Treatments | 2021-2025 | 396 | US 80 | 86.80 |
| Bipolar Disorder and Treatment | 2021-2025 | 484 | US 96 | 87.87 |
| Cannabis and Cannabinoid Research | 2021-2025 | 564 | US 263 | 87.12 |
| Attention Deficit Hyperactivity Disorder | 2021-2025 | 513 | US 156 | 85.21 |
| HIV, Drug Use, Sexual Risk | 2021-2025 | 982 | US 519 | 85.90 |
| Pharmaceutical Practices and Patient Outcomes | 2021-2025 | 911 | US 231 | 83.28 |
| Homicide, Infanticide, and Child Abuse | 2021-2025 | 155 | US 62 | 75.34 |
| Treatment of Major Depression | 2021-2025 | 769 | US 219 | 77.57 |
| Child and Adolescent Health | 2021-2025 | 773 | US 375 | 72.40 |
| Psychiatric care and mental health services | 2021-2025 | 339 | US 28 | 70.50 |
| Electroconvulsive Therapy Studies | 2021-2025 | 666 | US 171 | 60.63 |
| Gun Ownership and Violence Research | 2021-2025 | 773 | US 686 | 47.34 |
| Pharmacological Receptor Mechanisms and Effects | 2021-2025 | 788 | US 264 | 45.59 |